Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $57,325.20 in Stock

by · The Cerbat Gem

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Ansbert Gadicke sold 61,640 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $0.93, for a total transaction of $57,325.20. Following the completion of the sale, the insider owned 5,538,600 shares in the company, valued at approximately $5,150,898. This trade represents a 1.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ansbert Gadicke also recently made the following trade(s):

  • On Monday, November 17th, Ansbert Gadicke sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $54,207.95.
  • On Thursday, November 13th, Ansbert Gadicke sold 90,951 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $89,131.98.
  • On Wednesday, November 12th, Ansbert Gadicke sold 40,669 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $44,329.21.
  • On Tuesday, November 11th, Ansbert Gadicke sold 55,810 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $63,623.40.
  • On Monday, November 10th, Ansbert Gadicke sold 48,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total value of $57,312.60.
  • On Friday, November 7th, Ansbert Gadicke sold 68,480 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total value of $76,012.80.
  • On Thursday, November 6th, Ansbert Gadicke sold 54,452 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.21, for a total transaction of $65,886.92.
  • On Wednesday, November 5th, Ansbert Gadicke sold 47,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $58,499.00.
  • On Tuesday, November 4th, Ansbert Gadicke sold 140,488 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $171,395.36.
  • On Monday, November 3rd, Ansbert Gadicke sold 94,063 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $121,341.27.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL traded up $0.00 during trading on Monday, reaching $0.92. 519,418 shares of the company’s stock traded hands, compared to its average volume of 503,244. The stock has a market capitalization of $44.63 million, a P/E ratio of -0.57 and a beta of 0.72. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.38. The company has a 50 day moving average of $1.57 and a 200-day moving average of $1.34. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. On average, equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HOWL shares. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. Bank of America reduced their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. JMP Securities dropped their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

Read Our Latest Stock Report on HOWL

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HOWL. Quadrature Capital Ltd acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter valued at $48,000. Nuveen LLC acquired a new position in shares of Werewolf Therapeutics during the 1st quarter valued at $71,000. AQR Capital Management LLC acquired a new position in shares of Werewolf Therapeutics during the 1st quarter valued at $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $92,000. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Featured Articles